Watch Live

Tweet TWEET

A forward Look into the Year Ahead - Research Report on Boyd Gaming Corporation, Ameristar Casinos, Inc., Aegerion

     A forward Look into the Year Ahead - Research Report on Boyd Gaming
  Corporation, Ameristar Casinos, Inc., Aegerion Pharmaceuticals, Inc., ISIS
                Pharmaceuticals, Inc. and Avon Products, Inc.

PR Newswire

NEW YORK, March 12, 2013

NEW YORK, March 12, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Boyd
Gaming Corporation (NYSE: BYD), Ameristar Casinos, Inc. (NASDAQ: ASCA),
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), ISIS Pharmaceuticals, Inc.
(NASDAQ:ISIS) and Avon Products, Inc. (NYSE: AVP). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Boyd Gaming Corporation Research Report

Boyd Gaming generated $117.5 million cash last year. However, cash outflows
like major capital expenditures took a toll on their earnings. The company
also cites the unpredictability of their revenues, causing them to lay off an
uncertain number of employees in various parts of the country including Las
Vegas. But things are far from bleak for the company. They recently finished
the renovating the Kansas Star Casino, a key element of their recently
concluded $1.45 billion acquisition of Peninsula Gaming LLC. The casino will
provide the company a platform to access the Kansas market. Besides giving the
company more diversity, another reason to conclude that the acquisition will
be highly profitable is the property's recent performance. It generated a
total of $173.4 million in gambling revenue from late December 2011 to
November 2012, and Boyd Gaming CEO Smith expects it to provide even more
revenue for the company in the future.. The Full Research Report on Boyd
Gaming Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/5c85_BYD]

--

Ameristar Casinos, Inc. Research Report

Pinnacle had agreed to acquire Ameristar for $869 million in cash or $26.50
per share. However, some investors feel that the transaction may undervalue
the company, mainly due to the fact that Ameristar will soon open its 500
million Lake Charles, LA project in 2014. Furthermore, analysts set a high
target price for Ameristar, some even going as high as $33.00 per share.
Ameristar's board is optimistic about agreeing to Pinnacle's terms, saying
that the increased scale and diversification of the company will expand
opportunities and provide enhancements for guests. The Full Research Report on
Ameristar Casinos, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/46f2_ASCA]

--

Aegerion Pharmaceuticals, Inc. Research Report

Aegerion is the developer of Juxtapid, which treats a rare inherited
cholesterol disorder called homozygous familial hypercholesterolemia. The
company priced the pill between $235,000 to $295,000 per year, but could have
been higher with the anticipated competition. The pill was approved
unanimously by a panel of FDA officials. However, there are concerns
surrounding the company, as Juxtapid is its only product, putting it in a
vulnerable position. While Aegerion did make a last minute deal with
development partner Catalant, it's still a far cry compared to much larger
firms it competes with. The Full Research Report on Aegerion Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/7f1a_AEGR]

--

ISIS Pharmaceuticals, Inc. Research Report

Isis is the co-developer of Juxtapid's only competitor Kynamro, which costs
less at $176,000 a year. The pill was co-developed by pharmaceutical giant
Sanofi, and will be marketing it as soon as possible. However, the pill wasn't
well received by both the FDA and the European Medicines Agency, though it was
approved at a 9-6 vote. The EU agency cited cancer risks from the drug.
Nevertheless, the drug is expected to sell as much as $400 million, with Isis
getting 30 to 50 percent of the profits, depending on the total sales of the
drug. The Full Research ISIS Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/bf5f_ISIS]

--

Avon Products, Inc. Research Report

Avon faces several problems as of the moment: they have debt management
concerns, their margins are thin, and trends are not working to favor the
company's business model. To turn things around, Avon's new CEO, Sherilyn
McCoy, laid out several strategies that are expected to ensure the company's
future success. The plan includes reducing its overhead while simultaneously
gaining better hold in the markets where it does well, like Asia and Latin
America. These plans did not come at a humble price. To implement its
strategies, the company had to reduce its dividend by 74 percent. It also
plans to lay off 1500 employees in order to meet its plan to save $400 million
a year by the end of 2015. Lastly, it will exit the South Korea and Vietnam
markets, where it is not particularly growing. But despite these difficult
steps, the company is confident that these will help it grow in the long term,
making these sacrifices worth their price. Avon is scheduled to report its
fourth quarter earnings on February 11, and we'll see if the company's
strategies are working soon. The Full Research Report on Avon Products, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/3666_AVP]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@ investors-alliance.com
Main: +1-(408)-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.